Analyst Consensus ?
ConsensusBuy49 ratings
Bullish3367.3%
Neutral1632.7%
Bearish00.0%
Edwards Lifesciences Corporation · EW · FY2024 Q2 · Calendar Q3 2024
EW: TMTT growth offsets slower TAVR performance
EW’s growth case is increasingly dependent on TMTT momentum and new structural-heart products because TAVR growth has slowed. The current analysis supports durable longer-term drivers, but the lower TAVR guidance and execution risks make the near-term outlook less certain.
Reported After market closeNYSEHealthcare
$51.34B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.70
Consensus $0.69
EPS surprise
+1.4%
Reported versus consensus
Reported revenue
$1.39B
Consensus $1.65B
Revenue surprise
-16.2%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-31.3%
Event window
SPY move
-0.5%
Same window
Abnormal move
-30.8%
Stock minus SPY
Volume
13.9×
Versus trailing sessions
Subsequent drift
+19.4%
Up to 20 sessions
EWSPY benchmark
Ask FN2 about EW FY2024 Q2
Transcript, numbers and history already loaded
Why did EW fall 31.3% after beating EPS estimates in FY2024 Q2?What changed in EW's guidance and outlook in FY2024 Q2?Give me the bull and bear case for EW after FY2024 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the tone of the operating outlook became more cautious: TAVR growth missed expectations and full-year TAVR guidance was revised to 5–7%. At the same time, TMTT continued to grow rapidly, and EW added JenaValve and Endotronix to expand into aortic regurgitation and heart-failure monitoring.
Guidance delta
Management lowered full-year TAVR growth guidance to 5–7%, after previously raising full-year sales guidance to the high end of an 8–10% growth range.
Key takeaways
- Revenue grew 8% year over year, with TMTT driving most incremental sales.
- TMTT sales rose 75% year over year, supported by PASCAL and early EVOQUE launches.
- JenaValve and Endotronix broaden the pipeline, while Critical Care is being sold to Becton Dickinson.
Management priorities
- Commercialize EVOQUE in the United States and Europe.
- Advance RHEIA, early TAVR and other clinical-trial programs.
- Integrate JenaValve and Endotronix while progressing the Critical Care separation.
Follow EW with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$90.56Current
$70Low
$100.08Average
$140High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 26, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Sep 11, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Leerink Partners | Outperform | Market Perform | Upgrade | Jul 24, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Truist Securities | Hold | Hold | Maintain | Jul 16, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 8, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 2, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 27, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Apr 24, 2026 |
| Baird | Neutral | Neutral | Maintain | Apr 24, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 11, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 11, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 20, 2026 |
| UBS | Neutral | Neutral | Maintain | Jan 12, 2026 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Oct 29, 2025 |
| Jefferies | Buy | Hold | Upgrade | Oct 29, 2025 |
| Oppenheimer | Perform | Outperform | Downgrade | Oct 8, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 25, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 15, 2025 |
| B of A Securities | Buy | Neutral | Upgrade | Dec 16, 2024 |
| OTR Global | Positive | Mixed | Upgrade | Mar 26, 2024 |
| Raymond James | Market Perform | Outperform | Downgrade | Feb 6, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Apr 27, 2022 |
| Bernstein | Outperform | Market Perform | Upgrade | Mar 16, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Jan 7, 2022 |
| Atlantic Equities | Neutral | Neutral | Maintain | Apr 15, 2021 |
| CFRA | Buy | Buy | Maintain | Apr 24, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 31, 2020 |
| PiperJaffray | Overweight | Overweight | Maintain | Dec 9, 2019 |
| Bank of America | Buy | Buy | Maintain | Oct 24, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Sep 23, 2019 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 24, 2019 |
| Guggenheim | Neutral | Buy | Downgrade | Oct 2, 2018 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Feb 2, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Feb 2, 2017 |
| Cowen & Co. | Outperform | Outperform | Maintain | Dec 7, 2016 |
| Northland Securities | Outperform | Market Perform | Upgrade | Nov 8, 2016 |
| Northland Capital Markets | Outperform | Market Perform | Upgrade | Nov 8, 2016 |
| Leerink Swann | Outperform | Outperform | Maintain | Apr 4, 2016 |
| Nomura | Buy | Buy | Maintain | Mar 17, 2016 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Mar 7, 2016 |
| Sterne Agee | Neutral | Buy | Downgrade | Nov 7, 2014 |
| CRT Capital | Buy | Buy | Maintain | Oct 23, 2014 |
| Wunderlich Securities | Hold | Hold | Maintain | Apr 24, 2013 |
| Wunderlich | Hold | Hold | Maintain | Apr 24, 2013 |
| Lazard | Neutral | Buy | Downgrade | Apr 24, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $90.56. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $110 | $83.04 | +21.5% | Jul 28, 2026 |
| Piper Sandler | Analyst unavailable | $101 | $83.82 | +11.5% | Jul 24, 2026 |
| Leerink Partners | Mike Kratky | $101 | $83.82 | +11.5% | Jul 24, 2026 |
| Truist Financial | Richard Newitter | $95 | $86.78 | +4.9% | Jul 16, 2026 |
| RBC Capital | Analyst unavailable | $110 | $92.02 | +21.5% | Jul 13, 2026 |
| Evercore ISI | Analyst unavailable | $100 | $93.12 | +10.4% | Jul 6, 2026 |
| BTIG | Marie Thibault | $110 | $91.18 | +21.5% | Jun 30, 2026 |
| Barclays | Analyst unavailable | $110 | $84.15 | +21.5% | Apr 27, 2026 |
| Truist Financial | Analyst unavailable | $90 | $83.15 | -0.6% | Apr 24, 2026 |
| Evercore ISI | Vijay Kumar | $93 | $83.12 | +2.7% | Apr 24, 2026 |
| BTIG | Analyst unavailable | $100 | $79.72 | +10.4% | Apr 24, 2026 |
| Canaccord Genuity | William Plovanic | $85 | $79.72 | -6.1% | Apr 24, 2026 |
| Mizuho Securities | Analyst unavailable | $95 | $77.28 | +4.9% | Apr 13, 2026 |
| Truist Financial | Richard Newitter | $89 | $76.85 | -1.7% | Feb 11, 2026 |
| Goldman Sachs | David Roman | $95 | $77.05 | +4.9% | Feb 11, 2026 |
| Piper Sandler | Analyst unavailable | $100 | $77.05 | +10.4% | Feb 11, 2026 |
| UBS | Danielle Antalffy | $94 | $81.62 | +3.8% | Feb 4, 2026 |
| Stifel Nicolaus | Analyst unavailable | $110 | $84.35 | +21.5% | Jan 20, 2026 |
| Piper Sandler | Analyst unavailable | $98 | $84.35 | +8.2% | Jan 20, 2026 |
| UBS | Danielle Antalffy | $95 | $83.58 | +4.9% | Jan 12, 2026 |
| Robert W. Baird | Analyst unavailable | $90 | $83.69 | -0.6% | Jan 12, 2026 |
| Barclays | Analyst unavailable | $104 | $85.13 | +14.8% | Jan 12, 2026 |
| Goldman Sachs | David Roman | $108 | $84.58 | +19.3% | Jan 9, 2026 |
| Stifel Nicolaus | Rick Wise | $105 | $85.85 | +15.9% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $94 | $84.34 | +3.8% | Jan 5, 2026 |
| Wells Fargo | Analyst unavailable | $100 | $84.84 | +10.4% | Dec 18, 2025 |
| Canaccord Genuity | William Plovanic | $87 | $85.32 | -3.9% | Dec 17, 2025 |
| Robert W. Baird | David Rescott | $87 | $83.38 | -3.9% | Dec 16, 2025 |
| Barclays | Analyst unavailable | $103 | $86.19 | +13.7% | Dec 8, 2025 |
| UBS | Analyst unavailable | $92 | $86.58 | +1.6% | Dec 5, 2025 |
| RBC Capital | Shagun Singh | $100 | $87.34 | +10.4% | Dec 5, 2025 |
| Robert W. Baird | David Rescott | $88 | $85.78 | -2.8% | Dec 5, 2025 |
| Canaccord Genuity | William Plovanic | $89 | $85.78 | -1.7% | Dec 5, 2025 |
| Wells Fargo | Larry Biegelsen | $96 | $85.78 | +6.0% | Dec 5, 2025 |
| Stifel Nicolaus | Rick Wise | $100 | $85.78 | +10.4% | Dec 5, 2025 |
| Truist Financial | Richard Newitter | $92 | $85.78 | +1.6% | Dec 5, 2025 |
| BTIG | Marie Thibault | $103 | $85.78 | +13.7% | Dec 4, 2025 |
| Bernstein | Lee Hambright | $90 | $82.45 | -0.6% | Nov 3, 2025 |
| UBS | Analyst unavailable | $90 | $82.45 | -0.6% | Nov 3, 2025 |
| Canaccord Genuity | William Plovanic | $84 | $82.45 | -7.2% | Nov 3, 2025 |
| Raymond James | Jayson Bedford | $96 | $82.45 | +6.0% | Nov 3, 2025 |
| National Bank | Analyst unavailable | $92 | $82.46 | +1.6% | Oct 31, 2025 |
| Goldman Sachs | Analyst unavailable | $104 | $84.48 | +14.8% | Oct 31, 2025 |
| RBC Capital | Analyst unavailable | $95 | $83.29 | +4.9% | Oct 31, 2025 |
| Robert W. Baird | David Rescott | $83 | $83.29 | -8.3% | Oct 31, 2025 |
| Barclays | Analyst unavailable | $99 | $83.48 | +9.3% | Oct 31, 2025 |
| Jefferies | Matthew Taylor | $98 | $82.19 | +8.2% | Oct 29, 2025 |
| Truist Financial | Analyst unavailable | $87 | $83.08 | -3.9% | Oct 28, 2025 |
| Truist Financial | Analyst unavailable | $82 | $80.82 | -9.5% | Oct 27, 2025 |
| Evercore ISI | Analyst unavailable | $88 | $76.56 | -2.8% | Oct 7, 2025 |
| Stifel Nicolaus | Rick Wise | $85 | $74.41 | -6.1% | Sep 22, 2025 |
| Canaccord Genuity | William Plovanic | $75 | $76.04 | -17.2% | Apr 25, 2025 |
| Stifel Nicolaus | Rick Wise | $90 | $71.13 | -0.6% | Jan 29, 2025 |
| Bernstein | Lee Hambright | $74 | $74.15 | -18.3% | Jan 8, 2025 |
| Bernstein | Lee Hambright | $72 | $72.62 | -20.5% | Dec 5, 2024 |
| Truist Financial | Richard Newitter | $78 | $72.64 | -13.9% | Dec 5, 2024 |
| Canaccord Genuity | William Plovanic | $68 | $73.26 | -24.9% | Dec 5, 2024 |
| Goldman Sachs | David Roman | $80 | $68.63 | -11.7% | Oct 30, 2024 |
| Bank of America Securities | Travis Steed | $75 | $68.63 | -17.2% | Oct 30, 2024 |
| Citigroup | Joanne Wuensch | $81 | $69.05 | -10.6% | Oct 28, 2024 |
| Robert W. Baird | David Rescott | $73 | $69.63 | -19.4% | Oct 15, 2024 |
| Morgan Stanley | Patrick Wood | $70 | $68.26 | -22.7% | Oct 11, 2024 |
| Canaccord Genuity | William Plovanic | $66 | $65.49 | -27.1% | Oct 7, 2024 |
| Jefferies | Matthew Taylor | $70 | $67.23 | -22.7% | Sep 18, 2024 |
| Truist Financial | Richard Newitter | $71 | $68.13 | -21.6% | Sep 13, 2024 |
| Barclays | Matt Miksic | $80 | $66.81 | -11.7% | Sep 9, 2024 |
| Wells Fargo | Larry Biegelsen | $80 | $66.81 | -11.7% | Sep 9, 2024 |
| Daiwa | Narumi Nakagiri | $72 | $63.64 | -20.5% | Jul 31, 2024 |
| Citigroup | Joanna Wuensch | $83 | $63.74 | -8.3% | Jul 30, 2024 |
| Deutsche Bank | Pito Chickering | $85 | $60.58 | -6.1% | Jul 25, 2024 |
| Stifel Nicolaus | Rick Wise | $70 | $86.95 | -22.7% | Jul 25, 2024 |
| Piper Sandler | Adam Maeder | $73 | $86.95 | -19.4% | Jul 25, 2024 |
| Truist Financial | Richard Newitter | $110 | $89.5 | +21.5% | Jul 16, 2024 |
| Goldman Sachs | David Roman | $107 | $87.03 | +18.2% | May 30, 2024 |
| Deutsche Bank | Pito Chickering | $103 | $84.7 | +13.7% | May 14, 2024 |
| RBC Capital | Shagun Singh | $101 | $90.28 | +11.5% | Apr 15, 2024 |
| Mizuho Securities | Anthony Petrone | $105 | $91.51 | +15.9% | Apr 11, 2024 |
| Oppenheimer | Suraj Kalia | $100 | $92.85 | +10.4% | Mar 18, 2024 |
| Canaccord Genuity | Analyst unavailable | $76 | $78.21 | -16.1% | Feb 1, 2023 |
| Truist Financial | Analyst unavailable | $86 | $76.7 | -5.0% | Feb 1, 2023 |
| Morgan Stanley | Analyst unavailable | $95 | $76.32 | +4.9% | Jan 6, 2023 |
| Raymond James | Analyst unavailable | $83 | $75.32 | -8.3% | Dec 13, 2022 |
| Citigroup | Analyst unavailable | $92 | $75.26 | +1.6% | Dec 12, 2022 |
| Stifel Nicolaus | Rick Wise | $75 | $73.85 | -17.2% | Dec 5, 2022 |
| RBC Capital | Analyst unavailable | $105 | $75.98 | +15.9% | Nov 28, 2022 |
| RBC Capital | Shagun Singh Chadha | $118 | $70.87 | +30.3% | Oct 28, 2022 |
| Truist Financial | Richard Newitter | $120 | $100.54 | +32.5% | Jul 30, 2022 |
| Canaccord Genuity | Analyst unavailable | $137 | $111.59 | +51.3% | Apr 27, 2022 |
| Raymond James | Analyst unavailable | $124 | $111.86 | +36.9% | Apr 27, 2022 |
| RBC Capital | Analyst unavailable | $135 | $116.27 | +49.1% | Apr 27, 2022 |
| Leerink Partners | Analyst unavailable | $138 | $116.27 | +52.4% | Apr 27, 2022 |
| Evercore ISI | Vijay Kumar | $126 | $120.36 | +39.1% | Apr 6, 2022 |
| Bank of America Securities | Travis Steed | $130 | $111.98 | +43.6% | Mar 3, 2022 |
| Leerink Partners | Danielle Antalffy | $130 | $101.96 | +43.6% | Jan 27, 2022 |
| Stifel Nicolaus | Rick Wise | $120 | $101.96 | +32.5% | Jan 27, 2022 |
| Morgan Stanley | Cecilia Furlong | $136 | $101.96 | +50.2% | Jan 27, 2022 |
| Deutsche Bank | Pito Chickering | $113 | $108.63 | +24.8% | Jan 26, 2022 |
| Credit Suisse | Matt Miksic | $140 | $122.3 | +54.6% | Jan 7, 2022 |
| J.P. Morgan | Robbie Marcus | $140 | $122.12 | +54.6% | Dec 17, 2021 |
| Oppenheimer | Suraj Kalia | $135 | $120.34 | +49.1% | Dec 9, 2021 |
| Wells Fargo | Larry Biegelsen | $133 | $120.34 | +46.9% | Dec 9, 2021 |
| Cowen & Co. | Josh Jennings | $140 | $120.34 | +54.6% | Dec 9, 2021 |
| Jefferies | Anthony Petrone | $135 | $119.54 | +49.1% | Nov 8, 2021 |
Track every rating change on EW the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationEdwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems.…
Historical context
All EW earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the EW recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-26T20:50:42.373980+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-26T20:50:42.371189+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-26. For educational purposes only; not investment advice.